A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions

GlomerulonephritisIGA Nephropathy

Interventions

DRUG

Valsartan

Valsartan (80-160mg/day)

DRUG

Probucol

Probucol (750mg/day)

DRUG

Placebo

Trial Locations (1)

Guangdong General Hospital, Guangzhou

All Listed Sponsors

lead

Guangdong Provincial People's Hospital

OTHER

NCT00426348 - A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy | Biotech Hunter | Biotech Hunter